Longitudinal evaluation of liver stiffness and outcomes in patients with chronic hepatitis C before and after short- and long-term IFN-free antiviral treatment

References

• El-Sherif O, Jiang ZG, Tapper EB, et al. Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for Hepatitis C virus infection. Gastroenterology. 2018;154(8):2111–2121.e8.
   PubMed Web of Science ®Google Scholar
• Caviglia GP, Rosso C, Fagoonee S, et al. Liver fibrosis: the 2017 state of art. Panminerva Med. 2017;59(4):320–331.
   PubMed Web of Science ®Google Scholar
• European Association for Study of Liver. EASL recommendations on treatment of Hepatitis C 2018. J Hepatol. 2018;69(2):461–511.
   PubMed Web of Science ®Google Scholar
• Stasi C, Milani S. Non-invasive assessment of liver fibrosis: between prediction/prevention of outcomes and costeffectiveness. World J Gastroenterol. 2016;22(4):1711–1720.
   PubMed Web of Science ®Google Scholar
• Stasi C, Arena U, Vizzutti F, et al. Transient elastography for the assessment of liver fibrosis in patients with chronic viral hepatitis: the missing tool? Dig Liv Dis. 2009;41(12):863–866.
   Web of Science ®Google Scholar
• Stasi C, Milani S. Evolving strategies for liver fibrosis staging: non-invasive assessment. World J Gastroenterol. 2017;23(2):191–196.
   PubMed Web of Science ®Google Scholar
• Kemp W, Roberts S. FibroScan® and transient elastography. Aust Fam Physician. 2013;42:468–471.
   PubMedGoogle Scholar
• Agenzia Italiana del Farmaco. L’AIFA pubblica il nuovo Algoritmo per la terapia dell’Epatite C cronica. 2015 [cited 2015 Mar 25]. Available from: http://www.agenziafarmaco.gov.it/it/content/pubblicato-il-nuovoalgoritmola-terapia-dell’epatite-c-cronica
   Google Scholar
• Petrarca A, Rigacci L, Caini P, et al. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood. 2010;116(3):335–342.
   PubMed Web of Science ®Google Scholar
• de Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64(3):843–853.
   PubMed Web of Science ®Google Scholar
• Ferri C, Pileri S, Zignego AL. Hepatitis C virus infection and non-Hodgkin;s lymphoma In: Geodert J, editor. Infectious causes of cancer: targets for intervention. Totowa, NJ: Humana Press; 2000. 349–368.
   Google Scholar
• Zignego AL, Giannelli F, Marrocchi ME, et al. T(14;18) translocation in chronic hepatitis C virus infection. Hepatology. 2000;31(2):474–479.
   PubMed Web of Science ®Google Scholar
• Zignego AL, Ferri C, Giannini C, et al. Hepatitis C virus genotype analysis in patients with type II mixed cryoglobulinemia. Ann Intern Med. 1996;124(1 Pt 1):31–34.
   PubMed Web of Science ®Google Scholar
• Andreone P, Zignego AL, Cursaro C, et al. Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection. Ann Intern Med. 1998;129(4):294–298.
   PubMed Web of Science ®Google Scholar
• Pugh RNH, Murray-Lyon LM, Dawson JL, et al. Transection of the esophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646–649.
   PubMed Web of Science ®Google Scholar
• Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464–470.
   PubMed Web of Science ®Google Scholar
• Bachofner JA, Valli PV, Kröger A, et al. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index. Liver Int. 2017;37(3):369–376.
   PubMed Web of Science ®Google Scholar
• Tada T, Kumada T, Toyoda H, et al. Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. J Gastroenterol Hepatol. 2017;32(12):1982–1988.
   PubMed Web of Science ®Google Scholar
• Ogawa E, Furusyo N, Toyoda K, et al. The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. Antiviral Res. 2009;83(2):127–134.
   PubMed Web of Science ®Google Scholar
• Arima Y, Kawabe N, Hashimoto S, et al. Reduction of liver stiffness by interferon treatment in the patients with chronic hepatitis C. Hepatol Res. 2010;40(4):383–392.
   PubMed Web of Science ®Google Scholar
• Macías J, del Valle J, Rivero A, et al. Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin. J Antimicrob Chemother. 2010;65:2204–2211.
   PubMed Web of Science ®Google Scholar
• Wang JH, Changchien CS, Hung CH, et al. Liver stiffness decrease after effective antiviral therapy in patients with chronic hepatitis C: longitudinal study using FibroScan. J Gastroenterol Hepatol. 2010;25(5):964–969.
   PubMed Web of Science ®Google Scholar
• Martinez SM, Foucher J, Combis JM, et al. Longitudinal liver stiffness assessment in patients with chronic hepatitis C undergoing antiviral therapy. PLoS ONE. 2012;7(10):e47715.
   PubMed Web of Science ®Google Scholar
• Stasi C, Arena U, Zignego AL, et al. Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C. Dig Liver Dis. 2013;45(10):840–843.
   PubMedGoogle Scholar
• Stasi C, Piluso A, Arena U, et al. Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: a prospective pilot study. World J Gastroenterol. 2015; Mar 1421(10):3013–3019.
   PubMed Web of Science ®Google Scholar
• Dolmazashvili E, Abutidze A, Chkhartishvili N, et al. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience. Eur J Gastroenterol Hepatol. 2017;29:1223–1230.
   PubMed Web of Science ®Google Scholar
• Persico M, Rosato V, Aglitti A, et al. Sustained virological response by direct antiviral agents in HCV leads to an early and significant improvement of liver fibrosis. Antivir Ther. 2017;23(2):129–138.
   Web of Science ®Google Scholar
• Chan J, Gogela N, Zheng H, et al. Direct-acting antiviral therapy for chronic HCV infection results in liver stiffness regression over 12 months post-treatment. Dig Dis Sci. 2018;63(2):486–492.
   PubMed Web of Science ®Google Scholar
• Kobayashi N, Iijima H, Tada T, et al. Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. Eur J Gastroenterol Hepatol. 2018;30(5):546–551.
   PubMed Web of Science ®Google Scholar
• Rosso C, Caviglia GP, Ciruolo M, et al. Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single-center retrospective study. Minerva Med. 2019;110(5):401–409.
   PubMed Web of Science ®Google Scholar